Vittoria Biotherapeutics Announces FDA Clearance of IND Application for VIPER-101 to Treat T-Cell Lymphoma
VIPER-101 is an autologous, CD5 knock-out CAR-T therapy for the treatment of T-cell lymphoma
Initiating first-in-human Phase 1 trial in H1 of 2024